The legal inquiry, launched by the firm SueWallSt, focuses on whether Neumora executives misled shareholders regarding the drug's prospects. Despite the failure of the initial KOASTAL-1 trial, company leadership characterized the result as an anomaly during a March 2025 earnings call. This assessment preceded the subsequent collapse of the remaining clinical trials and a workforce reduction of approximately 35% announced on June 15, 2026.
Investors are now being asked to evaluate potential securities law violations stemming from these public representations. The investigation specifically targets the discrepancy between management's optimistic outlook regarding the drug's statistical viability and the undisclosed risks that eventually rendered the trials unsuccessful. Shareholders who incurred losses during this period are currently gathering records to determine if the company’s guidance failed to meet regulatory standards for transparency.
Comments (0)
No comments yet. Be the first!